Illegal wildlife trade is happening on a large scale to supply the parts and products of protected species such as leopards, pangolins, rhinos and tigers to serve as ingredients in some traditional Chinese medicines.
In this episode, EIA Legal and Policy Specialist Avinash Basker talks to Senior Press & Communications Officer Paul Newman about the findings of our new report, Investing in Extinction, and the reputation risk to which major international household names might be exposing themselves by investing in this aspect of the traditional medicine industry.